HIV Treatment Flashcards
Protease inhibitors
Lopinavir, Atazanavir, Darunavir, Fosamprenavir, Saquinavir, Indinavir, Ritonavir
*-Navir ending (Navir tease a protease)
Overall HIV treatment
HAART (highly active antiretroviral therapy)
Regimen of 3 drugs to prevent resistance:
1) 2 NRTIs
2) 1 NNRTI or 2) 1 protease inhibitor or 2) 1 integrase inhibitor
Mechanism of protease inhibitors
Prevent maturation of new viruses.
Assembly of the Virions depends on HIV-1 protease (pol gene)
Which cleaves the polypeptide products of HIV mRNA into their functional parts
Extra MOA of ritonavir
Boosts other drug concentrations by inhibiting cytochrome p450
Protease inhibitor toxicity
Hyperglycemia, GI intolerance (nausea, diarrhea), lipodystrophy, nephropathy.
Hematuria in indinavir
NRTIs (nucleoside reverse transcriptase inhibitors)
Tenofovir (TDF), Lamivudine (3TC), Zidovudine (AZT/ZDV), Didanosine (ddl), Stavudine (d4T), Emtricitabine (FTC)
Mech of NRTIs
Competitively inhibit nucleotide binding to reverse transcriptase and terminate the DNA chain (lack 3’ OH)
Tenofovir is nucleotide analog and does not have to be activated
Others are nucleoside analogs and do need activation (phosphorylation)
ZDV - prophylaxis and pregnancy (dec fetal transmission)
Toxicity of NRTIs
BM suppression (can be reversed with G-CSF and EPO) Peripheral neuropathy Lactic acidosis (nucleosides) Rash (tenofovir/ non-nucleosides) Anemia (ZDV)
NNRTIs
Neviparine
Efavirenz
Delavirdine
Mech of NNRTI
Bind to reverse transcriptase at site different from in NRTI. Do not require phosphorylation to be active or compete with nucleotides
Toxicity of NNRTIs
Same as NRTIs: BM suppression (can be reversed with G-CSF and EPO) Peripheral neuropathy Lactic acidosis (nucleosides) Rash (non-nucleosides)
Integrase inhibitors
Raltegravir
Mech of integrase inhibitors
Inhibits HIV genome integration into host cell chromosome by reversibly inhibiting HIV integrase
Toxicity of integrase inhibitors
Hypercholesterolemia